doi: 10.3390/jof3040057 31 Borba-SantosL
Ozempic litigation recognizes comprehensive compensation categories that reflect the full impact of pancreatitis and resulting gastroparesis: Medical Expenses : Coverage for emergency room visits, hospitalizations for pancreatitis treatment, diagnostic testing including CT scans and gastric emptying studies, surgical interventions, feeding tube placement, and ongoing gastroparesis management Future Medical Costs : Compensation for anticipated lifelong treatment needs, medical monitoring for pancreatic function, nutritional support, prescription medications, and potential surgical procedures Lost Wages and Earning Capacity : Recovery for time missed from work during acute pancreatitis episodes, ongoing disability from gastroparesis symptoms, reduced earning potential due to chronic illness, and early retirement forced by permanent disability Pain and Suffering : Compensation for physical pain from pancreatitis and gastroparesis, chronic nausea and vomiting, inability to enjoy meals, and diminished quality of life Emotional Distress : Damages for depression, anxiety, social isolation due to dietary restrictions, and psychological impact of living with an incurable digestive disorder Wrongful Death Damages : For families who lost loved ones to severe pancreatitis complications, including funeral expenses, loss of companionship, and lost financial support Settlement valuations emerging from early case assessments suggest a tiered structure based on injury severity and documented damages
Respiratory Side Effects : As mentioned earlier, some patients have reported respiratory issues while taking semaglutide
Current trend: Growing, fueled by post-pandemic health awareness and immune health focus
Conclusion: Treatment with GLP-1RA after BMS in patients living with diabetes and obesity was associated with reduced risk for primary MACE or mortality by 69%
